| Irinotecan and Bevacizumab for Recurrent Ovarian Cancer (NCT01091259) | NYU Langone Health | 2010-03-01 |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00872989) | SWOG Cancer Research Network | 2010-03-01 |
| E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 (NCT01133756) | Eisai Inc. | 2010-03-01 |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor (NCT01096381) | Vanderbilt-Ingram Cancer Center | 2010-03-01 |
| Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer (NCT01081951) | AstraZeneca | 2010-02-04 |
| Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 (NCT01074398) | Gynecologic Oncology Group | 2010-02-01 |
| Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy (NCT01570218) | Universidade Federal de Goias | 2010-02-01 |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction (NCT01083537) | University Health Network, Toronto | 2010-02-01 |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (NCT01065662) | Susana M. Campos, MD | 2010-02-01 |
| Characterization of Ovarian Cancer Stem Cell (NCT01367353) | National Taiwan University Hospital | 2010-01-01 |
| Pathway to Diagnosis of Ovarian Cancer (NCT01061619) | National Cancer Institute, Naples | 2010-01-01 |
| Clinical Database and Biobank of Patients With Gynecologic Neoplasms (NCT01267851) | Huazhong University of Science and Technology | 2010-01-01 |
| Abraxane/Bevacizumab (NCT01821859) | OHSU Knight Cancer Institute | 2010-01-01 |
| Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer (NCT01419210) | H. Lee Moffitt Cancer Center and Research Institute | 2010-01-01 |
| Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer (NCT01047891) | JSehouli | 2010-01-01 |
| How Our Immune System Can Help Fight Cancer (NCT01042847) | Winthrop University Hospital | 2010-01-01 |
| Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma (NCT01035658) | SCRI Development Innovations, LLC | 2010-01-01 |
| M. D. Anderson Symptom Inventory - Ovarian Cancer (NCT01037751) | M.D. Anderson Cancer Center | 2009-12-30 |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (NCT01033292) | Sanofi | 2009-12-01 |
| A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (NCT01033123) | Sanofi | 2009-12-01 |
| Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies (NCT01041235) | Azaya Therapeutics, Inc. | 2009-12-01 |
| Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer (NCT01097239) | Imperial College London | 2009-11-01 |
| Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer (NCT01096394) | Vanderbilt University | 2009-11-01 |
| AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer (NCT00976911) | Hoffmann-La Roche | 2009-10-29 |
| An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors (NCT01040312) | Daiichi Sankyo Co., Ltd. | 2009-10-15 |
| Ovarian Cancer Risk Estimation in Patients With Pelvic Mass (NCT00987649) | Fujirebio Diagnostics, Inc. | 2009-10-01 |
| Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer) (NCT01167842) | University of Washington | 2009-10-01 |
| A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer (NCT01016054) | Astellas Pharma Inc | 2009-10-01 |
| Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer (NCT01170299) | Royal Marsden NHS Foundation Trust | 2009-10-01 |
| A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (NCT01276548) | Samyang Biopharmaceuticals Corporation | 2009-10-01 |
| Guilford Genomic Medicine Initiative (GGMI) (NCT01372553) | The Moses H. Cone Memorial Hospital | 2009-10-01 |
| A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study (NCT00959647) | Genentech, Inc. | 2009-09-03 |
| Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) (NCT00959582) | Merck Sharp & Dohme LLC | 2009-09-01 |
| A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) (NCT00889382) | Astellas Pharma Inc | 2009-08-05 |
| Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer (NCT01003938) | NYU Langone Health | 2009-08-01 |
| Risk Education and Assessment for Cancer Heredity (NCT01346761) | University of Utah | 2009-08-01 |
| A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers (NCT00964756) | University of Alabama at Birmingham | 2009-08-01 |
| Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases (NCT01048814) | Precision Therapeutics | 2009-08-01 |
| Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study (NCT00946140) | Memorial Sloan Kettering Cancer Center | 2009-07-01 |
| 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors (NCT00967577) | Weill Medical College of Cornell University | 2009-07-01 |
| Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema (NCT00944944) | Memorial Sloan Kettering Cancer Center | 2009-07-01 |
| Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer (NCT01100372) | Medical University Innsbruck | 2009-07-01 |
| A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer (NCT00937560) | Hoffmann-La Roche | 2009-06-25 |
| Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse (NCT00926107) | Hellenic Cooperative Oncology Group | 2009-06-01 |
| Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer (NCT00986206) | Women and Infants Hospital of Rhode Island | 2009-06-01 |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer (NCT00910000) | Dana-Farber Cancer Institute | 2009-06-01 |
| Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer (NCT00826150) | Anchiano Therapeutics Israel Ltd. | 2009-06-01 |
| A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer (NCT00982631) | Radboud University Medical Center | 2009-06-01 |
| Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer (NCT00928642) | Henry M. Jackson Foundation for the Advancement of Military Medicine | 2009-06-01 |
| Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT00866697) | Novartis Pharmaceuticals | 2009-05-26 |
| Women's Activity and Lifestyle Study in Connecticut (NCT02107066) | Yale University | 2009-05-01 |
| Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer (NCT00856453) | Wake Forest University Health Sciences | 2009-05-01 |
| Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse (NCT00849667) | Morphotek | 2009-04-16 |
| Assessment of Screening Modalities for Gynecologic Cancers (NCT00879840) | National Cancer Institute (NCI) | 2009-04-09 |
| Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca (NCT00787488) | Mark Dewhirst | 2009-04-01 |
| Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (NCT00903630) | Masonic Cancer Center, University of Minnesota | 2009-04-01 |
| Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer (NCT00964626) | Russian Academy of Medical Sciences | 2009-04-01 |
| Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) (NCT00862836) | Genzyme, a Sanofi Company | 2009-04-01 |
| Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma (NCT01177501) | Assistance Publique - Hôpitaux de Paris | 2009-04-01 |
| Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life (NCT00870233) | Memorial Sloan Kettering Cancer Center | 2009-03-24 |
| Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer (NCT00866723) | Beth Israel Deaconess Medical Center | 2009-03-01 |
| Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients (NCT00856791) | Traws Pharma, Inc. | 2009-03-01 |
| Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study (NCT00686465) | Ontario Clinical Oncology Group (OCOG) | 2009-03-01 |
| Comparison of Standard of Care or Treatment on Protocol (NCT01010334) | New Mexico Cancer Research Alliance | 2009-03-01 |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer (NCT00855998) | Hadassah Medical Organization | 2009-03-01 |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies (NCT00856180) | Dana-Farber Cancer Institute | 2009-02-01 |
| Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer (NCT00867503) | University of Arizona | 2009-02-01 |
| Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery (NCT00842452) | Steven Waggoner, MD | 2009-02-01 |
| Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) (NCT00829959) | M.D. Anderson Cancer Center | 2009-02-01 |
| Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer (NCT00842582) | Loyola University | 2009-02-01 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors (NCT00819169) | NantCell, Inc. | 2009-01-16 |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity (NCT00825201) | City of Hope Medical Center | 2009-01-01 |
| AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (NCT00770536) | Amgen | 2009-01-01 |
| Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer (NCT01087268) | Royal Marsden NHS Foundation Trust | 2009-01-01 |
| The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression (NCT00854282) | National Taiwan University Hospital | 2009-01-01 |
| Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer (NCT01218490) | Institut Cancerologie de l'Ouest | 2008-12-09 |
| A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission (NCT00739661) | Genentech, Inc. | 2008-12-01 |
| Cost Utility Analysis in Recurrent Ovarian Cancer (NCT00813254) | M.D. Anderson Cancer Center | 2008-12-01 |
| Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer (NCT00692900) | University of Pittsburgh | 2008-12-01 |
| Lymphadenectomy In Ovarian Neoplasms (NCT00712218) | Philipps University Marburg | 2008-12-01 |
| Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers (NCT00803569) | Ludwig Institute for Cancer Research | 2008-11-14 |
| Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors (NCT00765973) | Spectrum Pharmaceuticals, Inc | 2008-11-10 |
| Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients (NCT01068483) | Novartis Pharmaceuticals | 2008-11-01 |
| Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval (NCT00657878) | National Cancer Institute, Naples | 2008-11-01 |
| Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer (NCT00660842) | National Cancer Institute, Naples | 2008-11-01 |
| Ovarian Dendritic Cell Vaccine Trial (NCT00703105) | Loyola University | 2008-10-01 |
| p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer (NCT00844506) | University Medical Center Groningen | 2008-10-01 |
| Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer (NCT00806156) | Nektar Therapeutics | 2008-10-01 |
| A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer (NCT00816764) | Astellas Pharma Inc | 2008-10-01 |
| Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors (NCT00788125) | City of Hope Medical Center | 2008-09-03 |
| Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. (NCT00753740) | NewLink Genetics Corporation | 2008-09-01 |
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT00753480) | Genentech, Inc. | 2008-09-01 |
| Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT00801320) | Beth Israel Deaconess Medical Center | 2008-09-01 |
| Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) (NCT00722592) | Endocyte | 2008-09-01 |
| An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (NCT00738699) | Morphotek | 2008-09-01 |
| Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma (NCT00768144) | Dana-Farber Cancer Institute | 2008-09-01 |
| Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer (NCT00753545) | AstraZeneca | 2008-08-28 |
| Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) (NCT00751205) | Bayer | 2008-08-01 |
| The Effect of TRA-8 on Ovarian Cancer Tissue (NCT00711932) | University of Alabama at Birmingham | 2008-08-01 |
| Study of Ramucirumab in Ovarian Cancer (NCT00721162) | Eli Lilly and Company | 2008-08-01 |